Company: PTHS
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001753926-25-000503
Chunk: 552

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1C
Chunk 552
---
Risk
management and strategy

We
are an R&D stage pharmaceutical company, with no commercial operations or revenue streams. Since our IPO, our sole business
activity has been ongoing research into our drug therapies. Therefore, we do not consider that we face significant cybersecurity
risk and have not adopted a formal cybersecurity risk management program or process for assessing cybersecurity risk currently.
We assess material risks from cybersecurity threats on an ongoing basis, including any potential unauthorized occurrence on or
conducted through our information systems that may result in adverse effects on the confidentiality, integrity, or availability
of our information systems or any information residing therein. As our Company grows, we plan to develop a more robust and detailed
strategy for cybersecurity in alignment with nationally accepted standards. We have not encountered cybersecurity challenges that
have materially impaired our operations or financial standing. For additional information regarding risks from cybersecurity threats,
please refer to Item 1A, “Risk Factors,” in this Annual Report on Form 10-K.

65 

Governance

Our
management and board of directors recognize the critical importance of maintaining the trust and confidence of our business partners
and employees, including the importance of managing cybersecurity risks as part of our larger risk management program. While all
of our personnel play a part in managing cybersecurity risks, one of the key functions of our board of directors is informed oversight
of our risk management process, including risks from cybersecurity threats. Our board of directors is responsible for monitoring
and assessing strategic risk exposure, and our executive officers are responsible for the day-to-day management of the material
risks that we face. In general, we seek to address cybersecurity risks through a cross-functional approach that is focused on
preserving the confidentiality, integrity, and availability of the information that we collect and store by identifying, preventing,
and mitigating cybersecurity threats and effectively responding to cybersecurity incidents when they occur.

Item
2. Properties.

Our
principal executive offices are located at 4400 Route 9 South, Suite 1000, Freehold, NJ 07728. The lease for our principal executive
offices is on a month-to-month basis. We believe our executive offices are adequate to meet our current needs, although we may
seek to negotiate new leases or evaluate additional or alternate space to support our operations and regulatory needs. We believe
appropriate alternative space will be readily available on commercially reasonable terms.

Item
3. Legal Proceedings

From
time to time, we may be involved in legal proceedings arising in the ordinary course of our business. We are not